Want to see TSE:PREV full AI Analyst Report?
Top Page
PreveCeutical Medical
(PREV)
Select Model
Select Model
Rating:38Underperform
Price Target:
C$0.01
▼(-30.00% Downside)
Action:Downgraded
Date:07/01/26
The score is driven primarily by very weak financial fundamentals (no revenue, rising losses, worsening cash burn, and negative equity with increasing debt). Technicals add further pressure as the stock trades below all major moving averages, signaling a persistent downtrend. Valuation provides limited support given negative earnings and no dividend yield data.
Positive Factors
R&D & IP-focused business model
PreveCeutical’s core focus on pharmaceutical R&D, drug delivery platforms and cannabinoid-related therapeutics is a durable structural strength: progressing intellectual property and early-stage candidates builds long‑term value and optionality for licensing or partner deals that can de‑risk commercialization over months.
Negative Factors
No commercial revenue
Absence of any reported revenue through 2025 is a fundamental weakness: it indicates lack of commercial validation and means the business has no internal cash generation to fund operations, increasing dependence on external financing and making long‑term sustainability contingent on successful trials or deals.
Read all positive and negative factors
Positive Factors
Negative Factors
R&D & IP-focused business model
PreveCeutical’s core focus on pharmaceutical R&D, drug delivery platforms and cannabinoid-related therapeutics is a durable structural strength: progressing intellectual property and early-stage candidates builds long‑term value and optionality for licensing or partner deals that can de‑risk commercialization over months.
Read all positive factors
PreveCeutical Medical (PREV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.97M
Dividend YieldN/A
Average Volume (3M)143.42K
Price to Earnings (P/E)―
Beta (1Y)-0.69
Revenue GrowthN/A
EPS Growth-36.36%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding598,186,950
10 Day Avg. Volume276,937
30 Day Avg. Volume143,419
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PreveCeutical Medical Business Overview & Revenue Model
Company Description
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid...
How the Company Makes Money
null...
PreveCeutical Medical Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -14.43K | -10.10K | -9.86K | -9.89K | -5.09K |
| EBITDA | -3.35M | -837.46K | -955.09K | -1.23M | -829.83K |
| Net Income | -1.58M | -1.17K | -1.27M | -1.48M | -1.73M |
Balance Sheet | |||||
| Total Assets | 1.45M | 225.66K | 181.51K | 189.14K | 161.20K |
| Cash, Cash Equivalents and Short-Term Investments | 10.24K | 59.14K | 1.43K | 5.62K | 16.06K |
| Total Debt | 4.68M | 4.46M | 3.83M | 3.23M | 2.93M |
| Total Liabilities | 7.69M | 6.86M | 5.96M | 4.82M | 4.27M |
| Stockholders Equity | -6.24M | -6.64M | -5.78M | -4.64M | -4.10M |
Cash Flow | |||||
| Free Cash Flow | -1.72M | -428.49K | -296.97K | -222.64K | -481.59K |
| Operating Cash Flow | -1.72M | -426.69K | -296.97K | -222.64K | -426.39K |
| Investing Cash Flow | -2.96K | -1.80K | 0.00 | 850.00 | -52.70K |
| Financing Cash Flow | 1.68M | 487.64K | 293.62K | 211.72K | 136.75K |
PreveCeutical Medical Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
39.13
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PREV, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.13 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PREV.
PreveCeutical Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$15.24M | -9.15 | -78.88% | ― | 125.00% | 25.37% | |
45 Neutral | C$13.85M | -2.64 | 75.85% | ― | 33.00% | 40.74% | |
43 Neutral | C$25.90M | -12.80 | 19.14% | ― | ― | 15.07% | |
38 Underperform | C$8.97M | -5.00 | 21.59% | ― | ― | -36.36% |
* Healthcare Sector Average
TSE:PREV
PreveCeutical Medical
0.02
-0.02
-50.00%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.11
-0.10
-47.50%
TSE:BETR
BetterLife Pharma
0.16
0.06
60.00%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.14
0.04
33.33%
PreveCeutical Medical Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
PreveCeutical Shifts to Semi-Annual Reporting Under CSE Pilot Program
Neutral
Apr 1, 2026
PreveCeutical Medical Inc., a health sciences company developing preventive and curative therapies from organic and nature-identical products, is advancing multiple RD programs, including dual gene therapies for metabolic diseases, peptide-based t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.